Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo?
PARTIALLY ADDRESSED
The debate highlighted that most SCFA studies use pharmacological doses (mM) rather than physiologically achievable concentrations. This dose-response gap is critical for translational potential and determines whether dietary/probiotic interventions could be therapeutically meaningful.
Source: Debate session sess_SDA-2026-04-16-gap-20260416-121711_20260416-134918 (Analysis: SDA-2026-04-16-gap-20260416-121711)
Landscape Summary:
Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo? is a 0.9 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo? — INVOKE-2 (completed)